First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study

George D. Demetri(Dana-Farber/Harvard Cancer Center), Axel Le Cesne(Institut Gustave Roussy), Sant P. Chawla(Sarcoma Oncology Center), Thomas Brodowicz(Vienna General Hospital), Robert G. Maki(Icahn School of Medicine at Mount Sinai), Bruce Allen Bach(Amgen (United States)), Dominic Smethurst(Amgen (United States)), Sarah Bray(Amgen (United States)), Yong-Jiang Hei(Amgen (United States)), Jean‐Yves Blay(Centre Léon Bérard)
European Journal of Cancer
January 11, 2012
10.1016/j.ejca.2011.12.008
Cited by 68Open Access
Full Text

Abstract

Related Papers

Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Robert Pitti, Scot A. Marsters, Siegfried Ruppert et al.|Journal of Biological Chemistry|1996|1.8k
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Pancras C.W. Hogendoorn, Nick Athanasou, S. Bielack et al.|Annals of Oncology|2010|717
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
J H Edmonson, Louise Ryan, Ronald H. Blum et al.|Journal of Clinical Oncology|1993|518
Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)
Avi Ashkenazi, Pamela M. Holland, S. Gail Eckhardt|Journal of Clinical Oncology|2008|410
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma
Ian Judson, John Radford, Martin Harris et al.|European Journal of Cancer|2001|390